Status:
COMPLETED
Validation of 70-gene MammaPrint Profile in Japanese Population
Lead Sponsor:
Agendia
Collaborating Sponsors:
Osaka General Medical Center
Conditions:
Breast Cancer
Eligibility:
FEMALE
29-70 years
Brief Summary
By using gene-expression profiling, Van't Veer and colleagues developed a 70-gene prognosis profile, MammaPrint, to identify breast cancer patients who are at low risk of developing distant metastases...
Detailed Description
Frozen tumor samples from 140 node-negative, breast cancer patients aged between 29 and 70 years at diagnosis are hybridized on MammaPrint array. Patients were treated with breast conserving therapy o...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Breast cancer patients
- Node-negative
- Treated with breast conserving therapy or mastectomy with axillary lymph node dissection at Osaka Medical Center for Cancer and Cardiovascular Diseases
Exclusion
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00904566
Start Date
April 1 2008
End Date
January 1 2009
Last Update
June 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka Medical Center for Cancer and Cadiovascular Diseases
Osaka, Japan